MDMX: a novel p53‐binding protein with some functional properties of MDM2. A Shvarts, WT Steegenga, N Riteco, T Van Laar, P Dekker, M Bazuine, ... The EMBO journal 15 (19), 5349-5357, 1996 | 805 | 1996 |
The Mkk3/6-p38–Signaling Cascade Alters the Subcellular Distribution of Hnrnp A1 and Modulates Alternative Splicing Regulation W van der Houven van Oordt, MT Diaz-Meco, J Lozano, AR Krainer, ... The Journal of cell biology 149 (2), 307-316, 2000 | 448 | 2000 |
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR … G Gebhart, LE Lamberts, Z Wimana, C Garcia, P Emonts, L Ameye, ... Annals of oncology 27 (4), 619-624, 2016 | 345 | 2016 |
Neutrophils kill antibody-opsonized cancer cells by trogoptosis HL Matlung, L Babes, XW Zhao, M van Houdt, LW Treffers, DJ van Rees, ... Cell reports 23 (13), 3946-3959. e6, 2018 | 309 | 2018 |
Isolation and identification of the human homolog of a new p53-binding protein, Mdmx A Shvarts, M Bazuine, P Dekker, YFM Ramos, WT Steegenga, G Merckx, ... Genomics 43 (1), 34-42, 1997 | 194 | 1997 |
Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? YWS Jauw, CW Menke-van der Houven van Oordt, OS Hoekstra, ... Frontiers in pharmacology 7, 131, 2016 | 165 | 2016 |
Apc1638N: a mouse model for familial adenomatous polyposis–associated desmoid tumors and cutaneous cysts R Smits, WH van Oordt, A Luz, C Zurcher, S Jagmohan-Changur, ... Gastroenterology 114 (2), 275-283, 1998 | 151 | 1998 |
Antibody positron emission tomography imaging in anticancer drug development LE Lamberts, SP Williams, AGT Terwisscha van Scheltinga, ... Journal of Clinical Oncology 33 (13), 1491-1504, 2015 | 128 | 2015 |
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer CW Menke-van der Houven, EC Gootjes, MC Huisman, DJ Vugts, C Roth, ... Oncotarget 6 (30), 30384, 2015 | 109 | 2015 |
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors CW Menke-van der Houven, C Gomez-Roca, C van Herpen, AL Coveler, ... Oncotarget 7 (48), 80046, 2016 | 86 | 2016 |
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study AH Eijkelboom, L de Munck, MJTFD Vrancken Peeters, MJM Broeders, ... Journal of hematology & oncology 14, 1-12, 2021 | 80 | 2021 |
ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment LE Lamberts, CW Menke-van der Houven van Oordt, EJ Ter Weele, ... Clinical Cancer Research 22 (7), 1642-1652, 2016 | 79 | 2016 |
Role of SR protein modular domains in alternative splicing specificity in vivo W van der Houven van Oordt, K Newton, GR Screaton, JF Cáceres Nucleic Acids Research 28 (24), 4822-4831, 2000 | 63 | 2000 |
Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies CM Venema, LH Mammatas, CP Schröder, M van Kruchten, G Apollonio, ... Journal of Nuclear Medicine 58 (12), 1906-1912, 2017 | 61 | 2017 |
Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse F Bensch, MM Smeenk, SC van Es, JR de Jong, CP Schröder, SF Oosting, ... Theranostics 8 (16), 4295, 2018 | 55 | 2018 |
The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype I Kramer, M Schaapveld, HSA Oldenburg, GS Sonke, D McCool, ... JNCI: Journal of the National Cancer Institute 111 (7), 709-718, 2019 | 53 | 2019 |
Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment EJ Van Helden, YJL Vacher, WN Van Wieringen, FHP Van Velden, ... European journal of nuclear medicine and molecular imaging 45, 2307-2317, 2018 | 53 | 2018 |
Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis RW Jansen, P van Amstel, RM Martens, IE Kooi, P Wesseling, ... Oncotarget 9 (28), 20134, 2018 | 51 | 2018 |
Immuno-PET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors CW Menke-Van Der Houven, A McGeoch, M Bergstrom, I McSherry, ... Journal of Nuclear Medicine 60 (7), 902-909, 2019 | 48 | 2019 |
PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab NE Makris, R Boellaard, A van Lingen, AA Lammertsma, ... Journal of Nuclear Medicine 56 (2), 249-254, 2015 | 48 | 2015 |